Clinical investigation of the GORE drug-coated PTA balloon catheter for CE mark approval

References

• Allaqaband S, Kirvaitis R, Jan F, et al. Endovascular treatment of peripheral vascular disease. Curr Prob Cardiol. 2009;34(9):359–476.
   PubMed Web of Science ®Google Scholar
• Fowkes FGR, Housley E, Cawood EHH, et al. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20(2):384–392.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. J Am Med Assoc. 2001;286(11):1317–1324. DOI:10.1001/jama.286.11.1317
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vascular Surg. 2007;45(Suppl S):S5–67.
   PubMed Web of Science ®Google Scholar
• Davies MG, Vykoukal D. Changing paradigms in the management of peripheral vascular disease: the need for integration of knowledge, imaging, and therapeutics. Computational surgery and dual training. (NY) (NY): Springer; 2009. p. 13–41.
   Google Scholar
• Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The san luis valley diabetes study. Circulation. 1995;91(5):1472–1479.
   PubMed Web of Science ®Google Scholar
• Margolis J, Barron JJ, Grochulski WD. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Managed Care Pharm. 2005;11(9):727–734.
   Google Scholar
• Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. J Vasc Health Risk Manag. 2007;3(2):229–234.
   PubMedGoogle Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease. Circulation. 2006;113(11):e463–654. DOI:10.1161/CIRCULATIONAHA.106.174526
   PubMed Web of Science ®Google Scholar
• Kugler CF, Rudofsky G. The challenges of treating peripheral arterial disease. Vascular Medicine. 2003;8(2):109–114.
   PubMed Web of Science ®Google Scholar
• Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vascular Surg. 1997;26(3):517–538. DOI:10.1016/S0741-5214(97)70045-4
   PubMed Web of Science ®Google Scholar
• Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation. 1991;83(2 Suppl):I70–80.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Rutherford B. Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 Pt 2):S1–296.
   PubMed Web of Science ®Google Scholar
• Johnston KW. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology. 1992;183(3):767–771.
   PubMed Web of Science ®Google Scholar
• Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for therapy of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation. 2000;102(22):2694–2699. DOI:10.1161/01.CIR.102.22.2694
   PubMed Web of Science ®Google Scholar
• Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358–1365. DOI:10.1161/CIRCULATIONAHA.107.735985
   PubMed Web of Science ®Google Scholar
• Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–699. DOI:10.1056/NEJMoa0706356
   PubMed Web of Science ®Google Scholar
• Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty evidence from the PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–840. DOI:10.1161/CIRCINTERVENTIONS.112.971630
   PubMed Web of Science ®Google Scholar
• Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10–19. DOI:10.1016/j.jcin.2013.05.022
   PubMed Web of Science ®Google Scholar
• Scheinert D, Schulte KL, Zeller T, et al. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovas Ther. 2015;22(1):14–21.
   PubMed Web of Science ®Google Scholar
• Schroeder H, Meyer DR, Lux B, et al. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheterization Cardiovasc Interventions Off J Soc Card Angiography Interventions. 2015;86(2):278–286.
   PubMed Web of Science ®Google Scholar
• Fanelli F, Cannavale A, Boatta E, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovas Ther. 2012;19(5):571–580. DOI:10.1583/JEVT-12-3926MR.1
   PubMed Web of Science ®Google Scholar
• Zeller T, Brechtel K, Meyer D-R, et al. Six-month outcomes from the first-in-human SELUTION sustained-limus-release drug-eluting balloon trial in femoropopliteal lesions. JVET. 2020;27(5):683–690. DOI:10.1177/1526602820941811
   Google Scholar
• Albrecht T, Waliszeski M, Roca C, et al. Two year clinical outcome of the CONSEQUENT trial: can femoropopliteal lesions be treated with sustainable clinical results that are economically sound? Cardiovasc Intervent Radiol. 2018;41(7):1008–1014.
   PubMed Web of Science ®Google Scholar
• Zeller T. A novel sustained limus release eluting balloon - 2-year data from the SELUTION SFA Trial. late breaking trial presentation at vascular interventional advances (VIVA) congress, las vegas 05.Nov.2019. 2019.
   Google Scholar
• Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245.
   PubMed Web of Science ®Google Scholar